Detailed analysis of outcomes and cost-effectiveness of SOC and second-line CAR-T in primary refractory/early relapse patients
| Treatment . | 2- and 5-Year outcomes . | Cost-effectiveness . | Incremental cost . | ICER . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2-Year OS . | 2-Year EFS . | 5-Year OS . | 5-Year EFS . | Life-years . | Effectiveness (QALYs) . | Incremental effectiveness (QALYs) . | Cost (2021 USD) . | |||
| SOC | 53% | 16% | 26% | 10% | 3.67 | 2.60 | – | 508 034 | – | – |
| Base case (6% rate of relapse after 24-mo EFS with second-line CAR-T) | ||||||||||
| Second-line CAR-T | 62% | 41% | 41% | 35% | 6.96 | 5.42 | 2.82 | 771 838 | 263 804 | 93 547 |
| Scenario 2 (second-line CAR-T has a low rate of relapse after 2 y) | ||||||||||
| Second-line CAR-T | 62% | 41% | 49% | 40% | 7.55 | 5.90 | 3.29 | 751 602 | 243 568 | 73 968 |
| Scenario 3: (second-line CAR-T has a high rate of relapse after 2 y) | ||||||||||
| Second-line CAR-T | 62% | 41% | 32% | 20% | 4.69 | 3.99 | 1.39 | 832 497 | 324 463 | 233 967 |
| Treatment . | 2- and 5-Year outcomes . | Cost-effectiveness . | Incremental cost . | ICER . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2-Year OS . | 2-Year EFS . | 5-Year OS . | 5-Year EFS . | Life-years . | Effectiveness (QALYs) . | Incremental effectiveness (QALYs) . | Cost (2021 USD) . | |||
| SOC | 53% | 16% | 26% | 10% | 3.67 | 2.60 | – | 508 034 | – | – |
| Base case (6% rate of relapse after 24-mo EFS with second-line CAR-T) | ||||||||||
| Second-line CAR-T | 62% | 41% | 41% | 35% | 6.96 | 5.42 | 2.82 | 771 838 | 263 804 | 93 547 |
| Scenario 2 (second-line CAR-T has a low rate of relapse after 2 y) | ||||||||||
| Second-line CAR-T | 62% | 41% | 49% | 40% | 7.55 | 5.90 | 3.29 | 751 602 | 243 568 | 73 968 |
| Scenario 3: (second-line CAR-T has a high rate of relapse after 2 y) | ||||||||||
| Second-line CAR-T | 62% | 41% | 32% | 20% | 4.69 | 3.99 | 1.39 | 832 497 | 324 463 | 233 967 |
First, the clinical outcomes (2- and 5-year OS and progression-free survival) are displayed. Effectiveness is then shown as life-years as well as QALYs. The costs displayed are the total lifetime costs related to RR-DLBCL treatment for each strategy. USD, US dollars.